{
  "docId": "019de073-cc15-73cb-b985-dc28972c4284",
  "docSlug": "df7f4367d54f16f4cdacd02ff486e30b",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 19,
  "pageCount": 31,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/19",
  "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284",
  "deckJsonHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284.json",
  "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.66,
        "y": 0.00292
      },
      "kind": "list",
      "text": "Favorable safety and tolerability data support longer-term use of MAT2203 with no evidence of renal toxicity seen with 6 weeks of oral MAT2203 treatment. Supports ability to treat with an AmB product for longer treatment duration than has been feasible to date",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10e62954-d784-4f2d-9231-920738800d86",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.058,
        "y": 0.00292
      },
      "kind": "list",
      "text": "Cohorts 2 and 4 EXCEEDED primary endpoint threshold. Potent antifungal activity (EFAs>0.20) when administered as part of a step-down and all-oral treatment regimen for cryptococcal meningitis through 6 Weeks of treatment",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d99eb54-abeb-434c-b9c7-1535b623ffc7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.36,
        "y": 0.00292
      },
      "kind": "list",
      "text": "Positive impact on overall survival at all timepoints. 90%+ survival across cohorts. Key endpoint for the upcoming Phase 3 registration trial",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2ef134f-2e8c-490a-b4cc-8be631e9f5e1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.916,
        "x": 0.042,
        "y": 0.0076
      },
      "kind": "paragraph",
      "text": "Data provide confidence for Phase 3 program in Cryptococcal Meningitis. Data provide additional evidence to potentially support the use of this safe and targeted delivery of AMB for the treatment of other severe and life threatening invasive fungal infections such as mucormycosis and aspergillosis which require longer-term antifungal treatment",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2b4fd88b-e8d2-4650-829e-de74e1d590b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.048,
        "w": 0.399,
        "x": 0.048,
        "y": 0.056
      },
      "kind": "title",
      "text": "EnACT Cohorts 2 and 4 Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2de9e375-7e1d-4c6b-b315-67fc07e22854",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.076,
        "w": 0.916,
        "x": 0.042,
        "y": 0.00188
      },
      "kind": "title",
      "text": "MAT2203 EnACT Phase 2 Trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41b80870-13f0-461b-8bf8-d492843f0381",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 19,
      "from": 14,
      "beatId": "7f5902f2-01bd-4712-8ad0-4cf1f9223757",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Slides 14-19 present results from the EnACT study",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}